Etomethazene (5-methyldesnitroetonitazene, 5-methyl etodesnitazene, Eto) is a benzimidazole derivative with opioid effects which has been sold as a designer drug over the internet since 2022, first being definitively identified in Sweden in January 2023.[1][2] It is an analogue of etonitazene where the nitro (NO2) group has been replaced by a methyl (CH3) group. While formal studies into its pharmacology have yet to be carried out, it showed far less potency than etonitazene itself. Etomethazene has an analgesic potency around 20 times that of morphine with a relatively short duration of about 120 min.[3][4][5]
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C23H31N3O |
| Molar mass | 365.521 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
editReferences
edit- ^ De Vrieze LM, Walton SE, Pottie E, Papsun D, Logan BK, Krotulski AJ, et al. (June 2024). "In vitro structure-activity relationships and forensic case series of emerging 2-benzylbenzimidazole 'nitazene' opioids". Archives of Toxicology. doi:10.1007/s00204-024-03774-7. PMC 11324687. PMID 38877156.
- ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
- ^ "Early signal alert: Emergence of online mentions of etomethazene" (PDF). National Drug Early Warning System. University of Florida, New York University, and Florida Atlantic University. 1 July 2022.
- ^ "5-methyl Etodesnitazene (citrate)". Caymanchem.com.
- ^ "Klassificeringsdokument Narkotika. Etometazen (5-metyletodesnitazen)" (PDF). Folkhälsomyndigheten (The Public Health Authority) (in Swedish).
 | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |